New Agents for the Treatment of Acute Lymphoblastic Leukemia

1. The Need for New Agents
Tim Eden

2. Identifying Targets for New Therapies in Children with Acute Lymphoblastic Leukemia
Shekhar Krishnan, Ashish Masurekar, Vaskar Saha

3. Preclinical Evaluation
Barbara Szymanska, Hernan Carol, Richard B. Lock

4. Design of Early-Phase Trials
James A. Whitlock, Terzah M. Horton

5. Strategies for Trial Design and Analyses
Maria Grazia Valsecchi, Paola Lorenzo

6. An Overview on Animal Models of ALL
Michael A. Batey, Josef H. Vormoor

7. Targeting Bcl-2 Family Proteins in Childhood Leukemia
Guy Makin, Caroline Dive

8. Targeting Leukemia Stem Cells and Stem Cell Pathways in ALL
Clare Pridans, Brian J. P. Huntly

9. Nucleoside Analogues
Pamela Kearns, Vaskar Saha

10. FLT3 Inhibitors as Therapeutic Agents in MLL Rearranged Acute Lymphoblastic Leukemia
Ronald W. Stam, Rob Pieters

11. The Role of Tyrosine Kinase Inhibitors in the Treatment of ALL
S. Wilson

12. Monoclonal Antibodies in Paediatric Acute Lymphoblastic Leukemia
Arend Stackelberg

13. Therapeutic Utility of Proteasome Inhibitors for Acute Leukemia
Joya Chandra, Claudia P. Miller

14. Targeting Epigenetic Pathways in ALL
Pamela Kearns

15. Incorporating New Therapies into Frontline Protocols
Paul S. Gaynon, Theresa M. Harned

Avainsanat: Biomedicine, Cancer Research, Pharmacology/Toxicology